发布于: 雪球转发：2回复：4喜欢：0
$Celladon Corporation(CLDN)$ announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. P value 0.81 [亏大了]

全部讨论

行者东东
2015-04-27 12:47

太危险了，赌药股，风险巨大。

Capricornus
2015-04-27 08:59

"We are surprised and very disappointed that Mydicar failed to meet the endpoints in theCUPID2 trial, and we are rigorously analyzing the data in an attempt to better understand theobserved outcome," Celladon's chief executive, Krisztina Zsebo, said in a statement on Sunday.

mineymo
2015-04-27 06:27

繼AERI後 又出現一個

岁月是值得怀念的
2015-04-27 05:52

失败了